PARP Inhibition for Gliomas (PI-4G or π4g)

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

November 14, 2023

Study Completion Date

February 6, 2024

Conditions
Recurrent GlioblastomaRecurrent AstrocytomaRecurrent OligodendrogliomaRecurrent Glioma
Interventions
DRUG

Niraparib

The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.

Trial Locations (1)

73104

Stephenson Cancer Center, Oklahoma City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Oklahoma

OTHER

NCT05297864 - PARP Inhibition for Gliomas (PI-4G or π4g) | Biotech Hunter | Biotech Hunter